Sarcopenia in Liver Disease: Current Evidence and Issues to Be Resolved

Sarcopenia in Liver Disease: Current Evidence and Issues to Be Resolved
复制标题

肝脏疾病中的肌肉减少症：当前证据和有待解决的问题

DOI：
10.1007/978-981-13-1435-3_19
复制
发表时间：
2018-01-01
期刊：
MUSCLE ATROPHY
影响因子：
--
通讯作者：
Yang, Changqing
Yang, Changqing
中科院分区：
其他
文献类型：
--
作者：
Song, Meiyi;Xia, Lu;Yang, Changqing

文献摘要

被引文献

相似文献

肌肉减少症是衰老和消耗性疾病患者的常见临床症状，其特征是骨骼肌质量减少。由于生活方式的改变，非酒精性脂肪肝（NAFLD）呈上升趋势。过去三十年，越来越多的证据证明肌肉减少症与NAFLD有关。在本章中，我们将总结肌肉减少症在 NAFLD 中的预测作用的新证据，并回顾肌肉减少症在 NAFLD 中的诊断价值、可行的机制和治疗策略。肌肉减少症是NAFLD的潜在危险因素，针对肌肉减少症可以在一定程度上使NAFLD受益。
Sarcopenia is a common clinical symptom in aging and patients with wasting diseases, characterized by a decreased skeletal muscle mass. As a consequence of lifestyle change, the nonalcoholic fatty liver disease (NAFLD) presents a rising trend. In the past three decades, increasing evidence has proved that sarcopenia is related to NAFLD. In this chapter, we will summarize the emerging evidence of the predictive role of sarcopenia in NAFLD and review the diagnosis value, feasible mechanism, and therapy strategies of sarcopenia in NAFLD. Sarcopenia is a potential risk factor for NAFLD, and targeting sarcopenia can benefit NAFLD to some extent.